This issue looks at MR severity as a predictor of therapeutic benefit in TMVI using the Tendyne system; the impact of elevated tricuspid valve inflow gradients after TTVR; TAVI vs SAVR in low surgical risk patients; the ANGIOLITE trial, a first-in-man comparison of the Angiolite SES with an EES in CAD; and an examination of stent thrombosis after endovascular revascularisation of the superficial femoral artery.